Skylark Bio expands gene therapy pipeline into CNS
Skylark Bio has revealed it is expanding its pipeline with SKY-AS, a differentiated gene therapy candidate designed to restore UBE3A expression in individuals with Angelman syndrome (AS).
SKY-AS represents the company’s first central nervous system (CNS) development programme and expands Skylark’s portfolio of precision, locally delivered genetic medicines.
AS is a rare monogenic neurodevelopmental disorder caused by loss of UBE3A gene function in neurons.
UBE3A is essential for normal neuronal development, synaptic function, and plasticity, biological processes that play critical roles in learning, memory, motor control and communication.
Preclinical data show SKY-AS restores synaptic communication machinery, driving complete and durable behavioural rescue across motor coordination and daily function in Angelman syndrome models.
“The addition of SKY-AS marks an important evolution for Skylark as we expand beyond hearing loss into serious neurological disorders with substantial unmet need,” said Jodi Cook, Chief Executive Officer of Skylark Bio. “With a growing body of data, we believe SKY-AS represents a promising opportunity to address the underlying cause and change the treatment paradigm in Angelman syndrome, and we look forward to advancing the programme toward an IND submission.”
To support the development of SKY-AS and a broadening CNS pipeline, neuroscientist and researcher Dr Edwin Weeber has joined Skylark Bio as Scientific Advisor. He is a recognised leader in Angelman syndrome research and UBE3A biology.
“Decades of research have established the central role of UBE3A in neuronal function and development,” said Dr Weeber. “SKY-AS is designed to deliver a functional copy of the UBE3A gene directly to neurons, increasing expression of the deficient protein, with the goal of supporting pathways involved in learning, memory, motor skills and communication.”
